We are proud to announce the official launch of Inverna Therapeutics, a Danish next-generation RNA splicing platform dedicated to transforming patient outcomes in severe genetic diseases, starting with its lead program addressing Huntington’s disease.

Emerging from the renowned Argobio and the prestigious University of Southern Denmark, Inverna Therapeutics is harnessing the revolutionary potential of sequence-based splice modulation, offering safer and more effective treatments for a wide range of debilitating conditions with high unmet medical needs.

📢 Discover more about our vision and pioneer work in the press release.